The estimated Net Worth of Nicole Vitullo is at least $13.9 Million dollars as of 24 January 2018. Ms. Vitullo owns over 71,235 units of Esperion Therapeutics stock worth over $47,189 and over the last 19 years she sold ESPR stock worth over $13,549,864. In addition, she makes $327,500 as Lead Independent Director at Esperion Therapeutics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Vitullo ESPR stock SEC Form 4 insiders trading
Nicole has made over 19 trades of the Esperion Therapeutics stock since 2006, according to the Form 4 filled with the SEC. Most recently she sold 4,250 units of ESPR stock worth $67,448 on 12 March 2021.
The largest trade she's ever made was buying 3,500,000 units of Esperion Therapeutics stock on 16 September 2011 worth over $7,000,000. On average, Nicole trades about 175,696 units every 79 days since 2006. As of 24 January 2018 she still owns at least 27,120 units of Esperion Therapeutics stock.
You can see the complete history of Ms. Vitullo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nicole Vitullo biography
Nicole Vitullo serves as Lead Independent Director of the Company. She joined Domain Associates, LLC, a venture capital firm with an exclusive focus on life sciences, in 1999 and became a Partner in 2004. From 1992 to 1999, Ms. Vitullo was Senior Vice President at Rothschild Asset Management, Inc. Ms. Vitullo is a director of a number of companies including Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), Celtaxsys Inc. and Cotera, Inc. She previously served on the boards of Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals), Durata Therapeutics (acquired by Actavis PLC) and VentiRx Pharmaceuticals (acquired by Celgene, Inc.). Ms. Vitullo received a B.A. and an M.B.A. from the University of Rochester.
What is the salary of Nicole Vitullo?
As the Lead Independent Director of Esperion Therapeutics, the total compensation of Nicole Vitullo at Esperion Therapeutics is $327,500. There are 7 executives at Esperion Therapeutics getting paid more, with Timothy Mayleben having the highest compensation of $1,080,850.
What's Nicole Vitullo's mailing address?
Nicole's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108.
Insiders trading at Esperion Therapeutics
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio..., and Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
What does Esperion Therapeutics do?
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
What does Esperion Therapeutics's logo look like?
Complete history of Ms. Vitullo stock trades at Alimera Sciences, Clovis Oncology Inc, Dicerna Pharmaceuticals Inc, Esperion Therapeutics, Evoke Pharma Inc, Marinus Pharmaceuticals Inc, Tandem Diabetes Care Inc, Vanda Pharmaceuticals Inc, Veracyte Inc, and Zogenix Inc
Esperion Therapeutics executives and stock owners
Esperion Therapeutics executives and other stock owners filed with the SEC include:
-
Timothy Mayleben,
President, Chief Executive Officer, Director -
Mark Glickman,
Chief Commercial Officer -
Richard B. Bartram,
CFO & Corp. Sec. -
Tracy Woody,
Independent Director -
Sheldon L. Koenig,
Pres, CEO & Director -
Richard Bartram,
Chief Financial Officer -
Dr. JoAnne Micale Foody FACC, M.D.,
Chief Medical Officer -
Nicole Vitullo,
Lead Independent Director -
Jay Shepard,
Independent Director -
Daniel Janney,
Independent Director -
Jeffrey Berkowitz,
Director -
Mark McGovern,
Independent Director -
Antonio Gotto,
Independent Director -
Alan Fuhrman,
Independent Director -
Ashley Hall,
Chief Development Officer -
Eric J. Warren R.Ph.,
Chief Commercial Officer -
Betty Jean Swartz,
Chief Strategy Officer -
Benjamin O. Looker,
Gen. Counsel -
Jerry Penn,
Exec. Director of Managed Care -
Roberta Peterson,
Sr. Director of National Accounts -
April Seiler,
Sr. Director of Project Management -
Dr. Joanne Micale Foody FACC, M.D.,
Chief Medical Officer -
Renee Marotta,
Head of Marketing -
Keith F. Lenden,
VP of Corp. Devel. & Strategy -
Benjamin Church,
Head of Corp. Communications & Investor Relations -
Dr. Kenneth J. Fiorelli,
Chief Technical Operations Officer -
Patrick G Enright,
Director -
Gilbert S Omenn,
Director -
Dov A Md Goldstein,
Director -
Mary Mc Gowan,
Chief Medical Officer -
Scott Braunstein,
Director -
Roger S Newton,
Executive Chairman, CSO -
Seth H. Z. Fischer,
Director -
Capital, Llc Boxer Asset Ma...,
-
Target N Vbb Biotech Ag Bio...,
-
Partners Viii, L.P.Alta Par...,
-
Kathleen K Schoemaker,
10% owner -
Partners Viii, L.P. Alta,
10% owner -
Capital Ii Lpaisling Capita...,
-
Parters Vii L Pblair James ...,
-
Capital Partners, Llc Longi...,
-
Noah L. Rosenberg,
Chief Medical Officer -
James C Blair,
10% owner -
Parters Vii L P Domain,
10% owner -
Vii Associates Lp Dp,
10% owner -
Brian H Dovey,
10% owner -
Brian K Halak,
10% owner -
Jesse I Treu,
10% owner -
Louis G Lange,
Director -
Joanne M. Foody,
Chief Medical Officer -
Sheldon L. Koenig,
President and CEO -
Benjamin Looker,
General Counsel -
Eric Warren,
Chief Commercial Officer -
Stephen Rocamboli,
Director -
Benjamin Halladay,
Chief Financial Officer -
J Martin Carroll,
Director